A clinical study of rituximab combined with autologous peripheral blood stem cell transplantation in treatment of B-cell non-Hodgkin′s lymphoma
10.3969/j.issn.1671-8348.2014.28.007
- VernacularTitle:利妥昔单抗联合APBSCT治疗B细胞性非霍奇金淋巴瘤的临床研究
- Author:
Jing WEN
- Publication Type:Journal Article
- Keywords:
B-cell,lymphoma;
hematopoietic stem cell transplantation;
rituximab
- From:
Chongqing Medicine
2014;(28):3718-3721
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of rituximab combined with autologous peripheral blood stem cell trans-plantation(APBSCT)in treatment of aggressive or refractory and recrrent B-cell non-Hodgkin′s lymphoma.Methods Forty-four patients with aggressive or refractory and recrrent B-cell non-Hodgkin′s lymphoma and treated with APBSCT in this department from Janauary 2007 to October 2013 were admitted.All the subjects were divided into 2 groups according to their own choice:22 pa-tients received rituximab treatment(treatment group)and 22 patients were treated without rituximab treatment(control group).For patients in treatment group,rituximab was used with chemotherapy or mobilization of stem cells before APBSCT for (2.9±1.1) times.After transplantation,IL-2 was used in both groups as maintenance treatment.And rituximab was used in the treatment group if the budget allows.Results The mononuclear cell count in treatment and control group was (13.01±4.22)×108/kg and (11.63±2.95)×108/kg(P=0.214).Hematopoietic reconstruction was successfully achieved in the both groups.No significant difference was found between 2 groups on the recovery time of neutrophilic granulocytes and platelets(P>0.05).All patients a-chieved complete remission(CR),at a median follow-up of 20 months(2-73 months),the disease relapsed in 2 patients in treatment group and 5 in control group.The 2-year overall survival rate in treatment group and control group were 95.0% and 75.1%,2-year progression-free survival rates were 82.4% and 74.5%,there were no significant difference between two groups(P=0.179, 0.393).Conclusion Rituximab combined with APBSCT in treatment of aggressive or refractory and recurrent B-cell lymphoma is feasible,however whether patients can benefit from long-term studies still need further research.Adding rituximab does not affect the hematopoietic stem cell collection and hematopoietic reconstitution.
